BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

Citi initiates coverage on 5 new biotech stocks

Citigroup added five biotech stocks, giving Buy ratings to Gilead and Vertex, while Amgen, Biogen, and Regeneron received Neutral ratings due to various market challenges.

RBC's top 10 questions and answers on biotech stocks

RBC Capital Markets reveals top 10 investor questions on biotech sector, focusing on FDA impact, major companies' strategies, upcoming trial data, and market sentiment.

Earnings call: Regeneron reports robust Q3 growth, Dupixent shines

Regeneron Pharmaceuticals reports an 11% revenue increase to $3.72 billion in Q3 2024, driven by strong Dupixent sales, ongoing product pipeline advancements, and robust financial health.

Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales

Sanofi's shares rose due to strong Q3 results, driven by vaccine sales and Beyfortus revenue, exceeding expectations and boosting outlook for 2024 and beyond.